We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Feb 2023 - 18 Feb 2023

Vaginal Insert Offers Alternative Treatment for Fecal Incontinence

By HospiMedica International staff writers
Posted on 02 Feb 2016
Print article
Image: The Eclipse vaginal insert in deflated (L) and Inflated (R) states (Phoyo courtesy of Pelvalon).
Image: The Eclipse vaginal insert in deflated (L) and Inflated (R) states (Phoyo courtesy of Pelvalon).
A novel vaginal insert for bowel control eliminates the need for surgery or an in-office procedure for the treatment of female fecal incontinence (FI).

The second-generation Eclipse System is comprised of a vaginal insert in the form of an inflatable balloon that is placed in the same location as a tampon or a diaphragm. The insert is composed of a base portion, an inflatable balloon portion, an inflation tube, and a self-closing Luer valve connection. The base portion positions the balloon and helps maintain the placement of the insert in the vagina. The balloon itself is made of thin walled silicone, with an enclosed, non-body contacting polyurethane liner to minimize air loss. The silicone inflation tube terminates in the self-closing Luer valve that connects to the patient pump.

The pump itself is fitted with a removable regulating valve that controls the amount of air introduced to the inflatable balloon. During inflation, the pump is squeezed seven to ten times to adequately fill the balloon, with any excess air vented out by the regulator. When inflated, the balloon exerts pressure through the vaginal wall, occluding the rectal area and providing immediate bowel control. The patient can inflate and deflate the device at home when needed, thus reducing the number of FI episodes and protecting from unwanted stool passage. The device is removed periodically for cleaning.

The insert is initially fitted using a sizing tool to assist with customizing insert size, and is inflated to the correct volume by a clinician to determine the correct regulator valve. A trial insert is available to allow patients to evaluate the therapy before deciding whether it works for them. The system is available in three base sizes and two balloon sizes, and is intended for women 18–75 years old who have had four or more FI episodes during a two-week period. The Eclipse System is a product of Pelvalon (Sunnyvale, CA, USA), and has been approved by the US Food and Drug Administration (FDA).

“With this FDA clearance for our next-generation Eclipse, we are excited to initiate the first phase of our commercial launch in select centers of excellence,” said Miles Rosen, CEO and co-founder of Pelvalon. “We believe that this early phase of partnership with thought and practice leaders in the field of pelvic floor disorders will ensure a smooth expansion down the road.”

“Eclipse is a nonsurgical therapy offering immediate bowel control that can be used early in the treatment pathway,” said Holly Richter, MD, director of the division of urogynecology and pelvic reconstructive surgery at the University of Alabama (Birmingham, USA). “Like the first-generation device, the next-generation Eclipse is an easily tried approach that fills a gap between lifestyle changes in diet and exercise and more invasive treatments. I'm excited that this new option will soon be available to my patients.”

FI is the inability to control bowel movements and is a common problem, especially among older adults. It affects women about twice as often as men, most probably due to childbirth, nerve or muscle damage in the pelvic region, or gastrointestinal disorders such as irritable bowel syndrome (IBS). First-line treatments include dietary changes, exercise, and medication; if the issue persists, patients may need to move on to more invasive and costly treatments, such as surgery, surgical implants, or injections.

Related Links:


Gold Supplier
Temperature Monitor
ThermoScan Temperature Monitoring Unit
Digital Video Colposcope
CS6/CS6 Pro
Capnograph/Pulse Oximeter
Handleld Capnograph/Pulse Oximeter
Mechanical Ventilator
NKV-550 Series

Print article



view channel
Image: A novel research study moves the needle on predicting coronary artery disease (Photo courtesy of Pexels)

AI-Enabled ECG Analysis Predicts Heart Attack Risk Nearly as well as CT Scans

Increased coronary artery calcium is a marker of coronary artery disease that can lead to a heart attack. Traditionally, CT scans are used to diagnose buildup of coronary artery calcium, although CT scanners... Read more

Critical Care

view channel
Image: The new biomaterial heals tissues from the inside out (Photo courtesy of UC San Diego)

Groundbreaking Biomaterial Injected Intravenously Repairs Cells and Tissue Damaged by Heart Attack and TBI

Following a heart attack, there is development of scar tissue, which affects muscle function and can result in congestive heart failure. However, there is still no established treatment available for repairing... Read more

Surgical Techniques

view channel
Image: The neuro-chip with soft implantable electrodes could manage brain disorders (Photo courtesy of EPFL)

Implantable Neuro-Chip Uses Machine Learning Algorithm to Detect and Treat Neurological Disorders

Using a combination of low-power chip design, machine learning algorithms, and soft implantable electrodes, researchers have produced a neural interface that can identify and suppress symptoms of different... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Point of Care

view channel
Image: Steripath improves the diagnostic accuracy and timeliness of sepsis test results (Photo courtesy of Magnolia)

All-in-One Device Reduces False-Positive Diagnostic Test Results for Bloodstream Infections

Blood cultures are considered the gold standard diagnostic test for the detection of blood stream infections, such as sepsis. However, positive blood culture results can be frequently wrong, and about... Read more


view channel
Image: The global patient positioning systems market is projected to reach USD 1.7 billion by 2027 (Photo courtesy of Pexels)

Global Patient Positioning Systems Market Driven by Increasing Chronic Diseases

The global patient positioning systems market is projected to grow at a CAGR of 4% from USD 1.4 billion in 2022 to USD 1.7 billion by 2027, driven by increasing technological advancements in medical devices,... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.